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Abstract 
The DNA base excision repair (BER) pathway repairs alkylation and oxidative DNA damage caused by en-
dogenous and exogenous agents, including chemotherapeutic agents. Upon removal of the damaged base AP 
endonuclease 1 (Apel), a critical component of the pathway cleaves the abasic site to facilitate repair. Apel is 
a multifunctional protein which plays a role 11ot only u1 DNA repair but it also functions as a reduction-oxi-
dation factor, known as Ref-1 in the literature, to increase the DNA binding ability of several transcription fac-
tors involved in different growth signaling pathways. Elevated levels of Apel have been linked to resistance 
to chemotherapy, poor prognosis, and poor survival. Reducing the amount of Apel protein in cancer cells and 
tumors using RNA interference and anti-sense oligonucleotide technology sensitizes mammalian tumor cells 
to a variety of laboratory and chemotherapeutic agents. Therefore, selective inhibition of Apel's DNA repair 
activity is a promising avenue to develop novel cancer therapeutics. Antioxid. Redox Signal. 11, 651-667. 
Introduction 
Importance of DNA repair pathways and cancer 
D NA REPAIR PATHWAYS PROTECT THE GENOME from damage caused by endogenous and exogenous DNA damaging 
agents, including chemotherapeutic agents and radiation 
damage (24, 44); the persistence of unrepaired DNA damage 
results in cell cycle arrest, apoptosis, and accumulation of 
mutations (47, 87). To protect cellular DNA, several DNA re-
pair pathways such as the Base Excision Repair (BER), Nu-
cleotide Excision Repair (NER), Mismatch Repair (MMR), 
Homologous Recombination (HR), and Nonhomologous 
End Joining (NHEJ) exist in the cell to ensure temporal and 
efficient repair of a variety of damage (24, 44). In addition, 
the importance of multiple DNA repair patl1ways is high-
lighted by several syndromes with a predisposition to can-
cer, which harbor germ line mutations in DNA repair genes. 
Currently, chemotherapy and radiation therapy are the 
mainstream treatment options available to treat cancers. 
Most of the chemotherapeutic drugs act by damaging DNA 
which leads to an accumulation of damage resulting in im-
paired cell signaling and ultimately causing cell death (56). 
Normal cells are proficient in all forms of DNA repair; how-
ever, deficiency of a particular DNA repair pathway in can-
cer cells can lead to elevated levels of other DNA repair path-
way proteins, leading to efficient repair of DNA damage and 
reducing the efficacy of cancer therapy. Cancer cells deficient 
in the proteins of the HR pathway, for instance, may be un-
able to repair damage efficiently through this pathway and 
may look to compensate for this deficiency by completing 
repair through alterna tive pathways such as the NHEJ or 
BER pathway (16, 40, 76, 82). The ability of cancer cells to 
identify and repair such DNA damage undermines the effi-
cacy of these agents, and acquired or intrinsic cellular resis-
tance to tl1ese clinical DNA-damaging agents is governed by 
the enhanced or elevated levels of DNA repair proteins (12, 
31, 59, 90). Although it may sound paradoxical to inhibit 
DNA repair pathvvay proteins since cancer promotion and 
deregulated cellular growth is aided by deficient DNA re-
pair pathways, a fine balance exists between induction of 
DNA dan1age and its efficient repair that is often responsi-
ble for resistance to chemotherapy (12, 92). Thus, inhibiting 
specific proteins from DNA repair pathways in cancer cells 
would provide us with a selective \.Vay to sensitize cancer 
cells to chemotherapeutic agents (90, 92). Additionally, com-
bining DNA repair inhibition with other current chemo-
therapy regimens (16) and thus developing targeted thera-
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FIG. 1. Overview of base excision re-
pair (BER) pathway. The BER pathvvay 
is responsible for repairing damage in-
duced by endogenous and exogenous 
agents, including chemotherapeutic 
agents. Repair is initiated by a damage-
specific DNA glycosylase, that removes 
the damaged base to generate 
apurinic/apyrimidinic (AP) sites. AP 
sites can also be generated as a resul t 
of spontaneous base hydrolysis. Mono-
functional DNA glycosylases remove 
the damaged base to generate an AP 
site, whereas bifunctional glycosylases 
in addition to excising the damaged 
base also nick the phospodiester back-
bone, 3' to the AP site. AP endonucle-
ase 1 (Apel), a critical component of the 
BER pathway, then processes the AP 
sites by hydrolyzing the backbone 5' to 
the AP site to genera te 3'0H and 5'dRP 
groups. The 5' dRP group is removed 
by the dRPase function of DNA poly-
merase f3 and it also fills in the correct 
base. Repair is completed by DNA lig-
ase III/XRCCl by sealing the nick. In 
the major short-patch (SP) BER path-
way, regular AP sites are repaired by the removal of the single damaged base. Modified or oxidized AP sites are repaired 
by the long-patch (LP) BER pathway where a flap of 3-8 nucleotides is displaced and excised by Fenl. DNA polymerase 
{3, o, ore then inserts the correct nucleotides and repair is completed by sealing of the nick by DNA ligase l. 
pies are generating robust interest. Here we describe the 
DNA Base Excision Repair (BER) pathvvay \Vith a focus on 
Apel as a targeted approach to cancer therapeutics. 
DNA base excision repair (BER) pathway 
The DNA base excision repair (BER) pathvvay repairs alky-
lation and oxidative damage caused by endogenous and ex-
ogenous agents, including radiation and chemotherapy-in-
duced damage (24, 44). The BER pathway recognizes and 
repairs single base lesions including N-alkylated purines 
(N3-methyladenine, N7-n1ethylguanine, and N3-methylgua-
nine), 8-oxo-7,8-d ihydroguanine(8-0xoG), thymine glycols, 
5-0H and 6-0H dihydrothymine, uracil glycol, 5-hydroxy-
cytosine, and urea residues, in addition to a number of ad-
ditional adducts (4, 24, 37). Repair of the damaged base is 
initiated by a DNA glycosylase (Fig. 1) which specifically 
recognizes and excises the damaged base. Different DNA 
glycosylases recognize specific and different types of base 
damage. Glycosylases are of two types-monofunctional 
and bifunctional glycosylases. Monofunctional glycosylases 
[e.g., N-methyl purine DNA glycosylase (MPG)] excise the 
damaged base to generate an apurinic/apyrimidinic (AP) or 
abasic site. In contrast, bi functional glycosylases, in addition 
to exhibiting glycosylase activity, also have an AP lyase func-
tion (20, 27). Bifunctional glycosylases such as 8-oxoguanine 
DNA glycosylase (OGGl), Nei endonuclease VII like, NEILl, 
NEIL2, and NTH not only excise the damaged base but also 
nick the phosphodiester backbone 3' to the AP site (24, 37). 
Removal of the damaged base by a DNA glycosylase creates 
an AP site, and AP sites are also generated by spontaneous 
base loss in the genome (29, 87). 
The second critical component of the pathway is the mul-
tifunctional protein apurinic/ apyrimidinic endonuclease 
(Apel). Following hydrolysis by a DNA glycosylase, Apel 
processes the AP site by making an incision in the phos-
phodiester backbone immediately 5' to the AP site. This in-
cision creates 3'0H and 5' deoxyribose phosphate (5'dRP) 
termini. At this stage, repair can proceed via one of two path-
ways (Fig. 1). The short-patch BER (SP-BER) pathway repairs 
regular AP sites. Tn the short-pa tch path\·vay, DNA poly-
merase {3 (Pol {3) removes the 5'dRP moiety via its dRPase 
activity and uses the 3'0H terminus to insert the correct base. 
Subsequently, DNA ligase III/XRCCl (X-ray cross-species 
complin1enting 1) seals the nick and repair is completed. The 
long-patch BER (LP-BER) pathway preferentially repairs 
modified (oxidized, reduced) AP sites. In this minor BER 
pathway. a flap of three to eight nucleotides surrounding the 
AP site is displaced. The correct nucleotides are inserted by 
DNA polymerase /3, o, ors, along vvith proliferating cell nu-
clear antigen (PCNA) and replication factor-C (RF-C). Fol-
lowing resynthesis, flap endonuclease 1 (FENl) removes the 
displaced strand and then the nick is sealed by DNA Ligase 
Tor DNA Ligase TTI/XRCCl (37). Oxidative DNA lesions can 
also be excised by the recently identified Neil glycosylases 
NEILl and NEIL2 that shov.r homology to the E. coli en-
donuclease VIII (5, 53-55, 69, 122). The AP sites generated 
are processed by Apel and subsequent repair is completed. 
While there are several different DNA glycosylases to excise 
the damaged base and generate AP sites, there is only one 
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Apel protein, which can process the AP sites generated and 
facilitate repair, thus emphasizing its significance in the BER 
pathway. 
The Ape1 protein, an essential component of 
the BER pathway 
Based on the method of incision, AP endonucleases can 
be classified into two classes. The Class I AP endonucleases 
are also known as AP lyases (or {3-lyases) as they process the 
AP sites by the ,B-elimination reaction and cleave the phos-
phodiester backbone 3' to the AP site, generating a 5' phos-
phate and a 3' a,{3-unsa turated aldehyde end. This AP lyase 
activity is usually associated with complex DNA glycosy-
lases which are responsible for repairing oxidatively dam-
aged DNA (27). The Escherichia coli endonuclease 111 and en-
donuclease Vlll (52) a nd the human homologue NTHl (57, 
58, 64) belong to this class of endonucleases. Class II AP en-
donucleases are the major class of endonucleases and are also 
known as hydrolytic endonucleases, as they hydrolyze the 
phosphodiester backbone 5' to the AP site, creating normal 
3'0H and 5' deoxyribose phosphate termini. Based on ho-
mology, Class TT AP endonucleases can be further classified 
into two families, the exonuclease III (xth) and the endonu-
clease lV (nfo) family. The exonuclease III family consists of 
human Apel in addition to enzymes from various phyla, and 
these enzymes possess a strong AP endonuclease activity (29, 
37, 110, 119, 133). In addition to the endonuclease activity, 
Apel also possesses a 3' -repair diesterase activity. Although 
this 3'-repair diesterase activity is much weaker (almost 200-
fold weaker) (20) than the AP endonuclease activity, it is im-
portant in the removal of 3' blocking lesions such as phos-
phoglycolate moieties in order to complete repair (20, 37, 42, 
104). ln the BER pathway, Apel is responsible for p rocess-
ing AP sites generated as a result of the action o f both types 
of DNA glycosylases (29, 32, 117). This processing of AP sites 
by Apel then faci litates complete repair of the damaged base. 
The endonuclease IV family of enzymes is the second major 
family of Class I.I AP endonucleases which include the£. coli 
endonuclease IV and Apnl from Saccharomyces cerevisine 
(yeast) which is responsible for 90°/o of AP endonuclease ac-
tivity in S. cerevisiae (37, 73, 108, 128). Apnl can repair both 
alkylation and oxidative damage, including oxidized abasic 
sites and unlike Apel, Apnl has a higher 3' repair-diesterase 
activity (43). Although the enzymes from both families share 
the AP endonuclease function, they do not share sequence 
or structural simi larity (29, 99). 
Functions of Ape1 
The AP endonuclease activity of Ape 1 
Apel is responsible for 95o/o of the endonuclease activity 
in the cell and is a critical part of both the short-patch and 
the long-patch BER pathway (29, 32, 117). Recognition of the 
damaged base by a monofunctional DNA glycosylase and 
its subsequent removal genera tes an AP site. This AP site is 
recognized by Apel that hydrolyzes the phosphodiester 
backbone 5' to the AP site, generating a 3'0H and a 5' de-
oxyribose phosphate (5' dRP) terminus. Subsequently, regu-
lar AP sites are repaired via the SP BER path\-vay whereby 
the 5' dRP moiety is removed by the dRPase function of Apel 
653 
or DNA Pol .B and repair is completed by insertion of the 
correct base by DNA Pol.Band sealing of the nick by DNA 
ligase 111/XRCCl. Modified (oxidized, reduced) and, to a 
lower extent, regular AP sites, are repaired via LP-BER where 
DNA polymerase ,B, I>, o r &, along with PC A and RF-C, fills 
in a patch of three to eight nucleotides. FE 1 cleaves the dis-
placed stretch of three to eight nucleotides and repair is com-
pleted by D A ligase I or DNA ligase ill / XRCCl (37). Apel 
is essential to complete the repair of AP sites v.rhich are gen-
erated by the action of different DNA glycosylases on a va-
riety of DNA lesions, including oxidative DNA lesions that 
can also be excised by the recently identified NElL glycosy-
lases (5, 53- 55, 122). Thus, Apel is functionally involved in 
the short-patch and long-patch BER pathv.rays. As discussed 
above, Apel has a s trong 5' AP endonuclease activity, in ad-
dition to which it also has a 3'-repair diesterase activity which 
is important for the removal of 3' blocking lesions generated 
as a result of the ,B-lyase function of DNA glycosylases in-
volved in the repa ir of oxidative or radiation-induced DNA 
damage (20, 37, 42, 104). Blocking lesions such as 3'-phosphate 
groups and 3'-phosphoglycolate moieties generated by the ac-
tion of oxidative agents such a bleomycin, radiation (IR), and 
also formed at sing le-strand breaks are removed by Apel's 3' -
phosdiesterase function so that the subsequent steps of BER 
can take place and repair can be completed (19, 20, 99, 104, 
124). ln addition to its hydrolytic and 3' -diesterase functions, 
Apel also has a 3'-5' exonuclease activity which is important 
to process 3' mispaired termini (22) and for the removal of 
unnatural nucleoside analogs (21, 23). 
AP sites formed as a result of the action of D IA glycosy-
lases can also be generated by spontaneous base hydrolysis 
in the cell (100), and Apel is required to further process these 
AP sites in order to complete repair. If left uruepaired, these 
AP sites can be cytotoxic and mutagenic as they can block 
the replicating polymerase (87, 132, 141). Thus, although AP 
sites can be generated by the action of several different dam-
age specific DNA g lycosylases, only Apel can process these 
AP sites and facilitate repair, thus emphasizing its signifi-
cance in the BER pathway. Furthermore, importance of Apel 
to normal cellular fun ctioning is highlighted by the embry-
onic lethality of Apel knockout mice (80, 138). Elevated lev-
els of Apel in cancer cells have been postulated to be area-
son for chemotherapeutic resistance (15, 37, 75, 77, 109, 114, 
121, 130) and inhibition of Ape1 has been shown to increase 
cell killing and apoptosis and also sensitize cancer cells to 
chemotherapeutic agents. Lnhibition of Apel using DNA an-
tisense and RNA interference technology is known to in-
crease cell killing and apoptosis and also sensitize cancer 
cells to chemotherapeutic agents (14, 81, 102, 129). These 
findings demonstrate the uniqueness of Apel as a molecu-
lar target in therapeutics. 
Other repair functions of Ape 1 
The multifunctional Apel protein has several other func-
tions accompanying its DNA repair and redox regulatory ac-
tivities. As part of its DNA repair activity, Apel removes 3' 
blocking lesions generated by DNA glycosylases v.rhich rec-
ognize oxidative damage (Oggl, Neil} (33, 37, 54) via its 3'-
phosphodiesterase and 3' -phosphatase activities to facilitate 
complete repa ir. Apel also possesses a 3'- 5' exonuclease ac-
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tivity which is important for the removal of deoxyribonu-
cleoside analogs which can impede repair (19, 22, 23, 34). In 
addition to the afore mentioned functions, Apel has been 
shown to inhibit the activation of PARPl (poly(ADP-ri-
bose)polymerase 1) during oxidative damage repair, thus 
preventing the cells from undergoing apoptosis (105). A re-
lationship between Bcl2 and Apel resulting in decreased re-
pair has been reported (72) in addition to negatively regu-
lating the parathyroid hormone gene (PTH) (13, 25, 78, 101), 
being involved in granzyme A (GzmA) aided NK cell-me-
diated killing (39, 93) and it has been implicated in nucleo-
tide incision repair (NIR) (65, 66). Apel has also been sug-
gested to play a role in negatively regulating the Rael/ 
GTPase to prevent oxidative stress (103) and to regulate vas-
cular tone and endothelial NO production (71) (Fig. 2). 
The redox function of Ape 1 
In addition to the AP endonuclease function of Apel, it also 
functions as a reduction/oxidation (redox) signaling factor 
(Fig. 3) and is therefore also referred to as Redox effector fac-
tor-1 (Ref-1) in the literature (1, 2, 135, 136). Ref-1 reduces key 
cysteine residues located in the DNA binding domains of tran-
scription factors such as APl (Fos/Jun), p53, HIF-la, and oth-
ers (3, 36, 48, 62, 63, 79, 96, 125, 126, 135, 136, 140). This re-
duction of the critical cysteines in the DNA binding domains 
of the transcription factors increases their DNA binding abi l-
ity. Increased DNA binding ability of these transcription fac-
tors activates them which leads to the transcription of several 
key genes important for cell survival and in cancer promotion 
and progression (37, 124). Thus, the multifunctional Apel pro-
tein not only functions in and interacts with the proteins in-
volved in the repair of damaged DNA, it also interacts with 
proteins involved in growth signaling path,~rays and path~rays 
known to be involved in tumor promotion and progression. 
The redox function of Apel as a target in cancer has not been 
as extensively investigated as the DNA repair function of Apel. 
However, given its role in activating transcription factors such 
as NFKB, AP-1, and HIF-1a etc, inhibiting the redox ability of 
Apel should lead to decreased signaling via these transcrip-
tion factors of the signaling pathways involved in cancer pro-
motion and progression. 
The repair and redox functions of Ape 1 are distinct from 
each other 
As discussed previously, Apel is a multifunctional pro-
tein with roles in DNA repair as well as in redox signaling 
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in the cell. These two important functions of Apel are func-
tionally distinct from each other and are encoded by distinct 
regions of the protein (137). The AP endonuclease or DNA 
repair activity which is a c1itical component of the BER path-
way resides in the C-terminal portion of the protein. The AP 
endonuclease activity is mediated by the active site residues 
His 309, Glu 96, Asp 238, and Asp 308, where H309 is the 
catalyt ic residue (6-8, 11, 37, 45, 50, 88, 98). The redox regu-
latory activity of Apel which is important for the control 
transcription factors resides in the N-terminal sequences of 
the protein and a conserved Cys 65 residue is crucial for this 
function of Apel (9, 35, 37, 45). These t\.vo important func-
tions of Apel can be functionally separated from each other, 
and disruption of one of its activities does not affect the other. 
Several reports have shovvn that disruption of Cys 65 by site-
directed mutagenesis (21, 35) or by using a redox specific in-
hibitor, impairs the redox function of Apel but does not af-
fect its DNA repair ability (112, 143). 
Apel is ubiqui tously expressed and though there are sev-
eral reports sho~ring that Apel is localized to the nucleus, 
cytoplasmic localization of Apel has also been reported (34, 
74, 97, 113, 134). In addition to exhibiting a heterogeneous 
and complex pattern of staining, localization of Apel is tis-
sue specific and even differs bet\~reen neighboring cells (113, 
134). Localization of Apel in the cytoplasm may be associ-
ated ~rith its role as a mitochondrial DNA repair protein (37, 
97, 124). Noting Apel's role in redox control of transcription 
factors, presence of Apel in the cytoplasm may be impor-
tant to maintain these transcription factors in a reduced state 
prior to their transport to the nucleus (34). Apel has also 
been shown to accumulate in the nucleus and mitochondria 
in response to DNA damage (97). Thus, it appears that the 
intracellular localization of Apel is regulated; however the 
significance of its subcellular localization is still not well un-
derstood. 
Inhibition of DNA Repair as a Target in Cancer 
DNA repair pathways are important to maintain the ge-
nomic integrity as highlighted by several cancer predispos-
ing syndromes which harbor gerrnline mutations in DNA 
repair genes (24, 44, 59). Currently, chemotherapy and radi-
ation therapy are the mainstream treatment options avail-
able to trea t cancers. The cytotoxic effects of most chemother-
apeutic agents and radiation are rela ted to their ability to 
induce DNA damage. The ability of cancer cells to identify 
and efficiently repair such DNA damage undermines the ef-
FIG. 2. The complex network of protein-protein interactions of Apel . Apel is a multifunctional protein with a role in 
DNA repair to maintain genomic integrity and a function in cellular redox signaling to activate key transcription factors, 
leading to changes in expression of genes involved in crucial cellular processes. In addition to these functions, Apel inter-
acts \.vith several different proteins from the BER path\.vay and other DNA repair and signaling pathways to create a com-
plex mesh of direct and indirect interactions. This matrix is a graphical representation of the molecular relationships between 
genes or gene products (proteins or complexes). Each gene or protein is represented as a node and the lines (edges) joining 
them represent the biological relationships beh-veen them. At least one reference from the literature, from a textbook, or from 
canonical information stored in the Ingenuity knowledge base corroborates each edge. Orthologs of a gene (human, mouse, 
and rat) are represented as a single node in the network but are stored as separate objects in the Ingenuity knowledge base. 
The various shapes of the nodes represent the functional class of tha t gene product. The nature of an edge is descriptive of 
the nature of the relationship between the nodes (e.g., solid line indicates a direct relationship, dashed line indicates an indi-
rect relationship, etc). This interaction network \~ras generated through the use of Ingenuity Pathways Analysis (Ingenuity 
Systems®, www.ingenuity.com). (For interpretation of the references to color in this figure legend, the reader is referred to 
the ~reb version of this article at www.liebertonline.com/ars). 
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FIG. 3. Role of Apel in D NA rep air and red ox regulation. Apel is a multifunctional protein that plays an important role 
in the repair of damaged DNA to maintain genomic integrity. Imbalancing or disrupting the DNA repair ability of Apel 
can lead to an accumulation of mutations and eventually result in death. In addition to Apel's role in repair of damaged 
bases, it also plays a role in cellular redox regulation where it functions as a reduction-oxidation (redox) factor and is also 
kno,-vn as Ref-1. Apel reduces critical cysteine residues in the DNA binding domains of several key transcription factors 
such as p53, NFKB, A Pl, increasing their DNA binding ability '~'hich results in a change in the expression of genes involved 
in key cellular processes. 
ficacy of these agents (111, 127). Therefore, inhibiting DNA 
repair proteins leading to reduced repair of damaged DNA 
in cancer cells is an attractive approach to combat chemother-
apeutic resistance and to increase efficacy of therapy. Al-
though it may sound contradictory to inhibit DNA repair 
pathway proteins, since cancer promotion and deregulated 
cellular growth is aided by deficient DNA repair pathways, 
it actually makes sense to block DNA repair, given the pre-
dominance of DNA damage during cancer treatments with 
chemotherapy and IR, which would allo'~' for increased ef-
ficacy of the DNA damaging agent (12, 92). Thus, inhibiting 
specific proteins from selected DNA repair path~rays in can-
cer cells could provide us \Vith a selective way to sensitize 
cancer cells to chemotherapeutic agents and also combat 
their resistance to chemotherapeutic agents (90, 92). 
Consequences of inhibiting the BER pathway in cancer 
The BER pathway is responsible for repairing DNA dam-
aged by endogenous and exogenous agenl'> including 
chemotherapeutic agents. In addition to repairing damaged le-
sions, the proteins of the BER path~ray exhibit several impor-
tant protein-protein and DNA-protein interactions (38) and a 
delicate balance exists between the levels of all the BER pro-
teins (49). In cancer cells, the upregulation of the BER proteins 
results in imbalanced repair and can lead to resistance to 
chemotherapeutic agents; modulating or inhibiting the activi-
ties of these BER proteins can lead to deregulated repair, re-
sulting in sensitivity to chemotherapy agents. Ho,-vever, tl1e 
central idea that presence of robust DNA repair mechanisms 
leads to resistance to chemotherapeutic agents (12, 26, 31, 56, 
82, 92, 120) has been challenged by some studies. Roth et al. 
{116) showed that absence of Aag (3MeA DNA glycosylase) in 
the bone marrow (BM) cells of the myeloid lineage from Aag 
-/- mice are resistant to alkylating agents (MMS), as compared 
to the wild-type BM cells. They speculated that initiation of re-
pair by Aag and subsequent incomplete repair of the lesions 
in ~rild-type BM cells may be more toxic than the inability of 
Aag null BM cells to initiate repair of these damaged lesions. 
This effect was specific to the myeloid lineage of the Aag -/-
mice and was not observed in embryonic stem cells (ES), pri-
mary embryonic fibroblasts (PEF) and cells from the lymphoid 
lineage in the BM, indicating that this effect is tissue specific, 
as \-vell as likely lesion specific. In general, it has been shown 
that presence of DNA repair contributes to resistance to 
chemotherapeutic agents. DNA glycosylases show quite a bit 
of functional redundancy (80), and the action of all the DNA 
glycosylases results in the formation of AP sites. For instance, 
overexpression of 3MeA DNA glycosylases in S. cerevisiae and 
E. coli leads to increased sensithrity to alkylating agents and 
spontaneous mutations, possibly due to an imbalance between 
the levels of the DNA glycosylase and Apel proteins and also 
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FIG. 4. Consequences of inhibiting Apel and BER. DNA glycosylases initiate BER and their action results in the for-
mation of AP sites. These AP sites are further processed by Apel. However, failure to complete the repair of these AP sites 
cause them to accumulate and such accumulated AP sites can lead to cytotoxicity and increased apoptosis. High levels of 
Apel in cancer cells have been linked to resistance to che1notherapy, poor prognosis, and survival. Thus, inhibiting Apel 
leads to sensitization of cancer cells to chemotherapeutic agents. 
due to the build-up of unrepaired AP sites (116). Accumula-
tion of these unrepaired AP sites can lead to (Fig. 4) single-
strand breaks, increased apoptosis, and enhanced cytotoxicity 
(47). Apel is required to process these AP sites and along with 
the rest of the BER proteins can facilitate the ensuing comple-
tion of repair. Increased expression of the BER pathway pro-
teins in cancer cells can result in efficient repair of damaged 
lesions and can reduce the effectiveness of chemotherapeutic 
agents. Therefore, keeping in mjnd the importance of the BER 
pathway in the repair of damage induced by chemotherapy, 
exploiting the BER pathway and its proteins by inhibiting them 
would increase the efficacy of chemotherapy, thus making it 
an attractive target to develop novel means in order to com-
bat chemotherapeutic resistance (120). 
Inhibition of the DNA Repair Function of Ape1 as a 
Rational Cancer Target 
There are several reasons why Apel is a rational target for 
chemotherapeutic agents: (a) overexpression of Apel leads 
to chemoresistance; (b) cells that lack Apel are not viable; 
(c) knockdown or blockage of Apel activity sensitizes can-
cer cells to chemo agents such as temozolomide (TMZ) and 
bleomycin. Elevated levels of Apel in cancer cells have been 
postulated to be a reason for chemotherapeutic resistance 
(14, 37, 75, 77, 109, 114, 121, 130). The importance of Apel's 
function in the DNA BER pathv.ray is observed from the 
lethality of Apel knockout mice (80, 138). Specifically knock-
ing down or inhibiting Apel using RNA interference and 
anti-sense oligonucleotide technology hypersensitizes mam-
malian cancer cells to several laboratory and clinical DNA 
damaging agents, such as methyl methane sulfonate (MMS), 
hydrogen peroxide (H20 2), bleomycin, TMZ, and gemc-
itabine (14, 15, 75, 81, 87, 114, 121, 129, 130)- The decrease in 
cancer cell proliferation and survival after knocking do'~'n 
Apel reiterates the importance of Apel function. Although 
these data demonstrate Apel is a feasible target for inhibi-
tion to sensitize cancer cells, s tudies involving a reduction 
in Apel mRNA and protein do not allow us to dissect which 
function, repair or redox, of Apel is important for cell 
. . 
growth, cancer promotion and/ or progression (14, 15, 75, 81, 
87, 114, 121, 129, 130). Fung et al. (47) demonstrated that de-
pletion of Apel from cells using siRNA technology causes 
increased apoptosis and decreased cell growth of cancer 
cells. They further demonstrated that functional comple-
mentation '~'ith a yeast homologue (Apnl) of Apel deficient 
in redox activity could restore proliferation potential of the 
cells. Another report demonstrated that expressing a domi-
nan t-nega ti ve repair deficient Apel protein in cells sensitizes 
them to chemotherapeutic agents (94). Several studies con-
ducted using a small molecule that binds to AP sites in DNA 
[methoxyamine (MX)) and blocks Apel's ability to cut the 
sugar-phosphate backbone sensitized cancer cells to 
chemotherapeutic agents (41, 84, 85, 123). Conversely, as we 
learn more about the redox function of Apel, we appreciate 
its critical role in cell grov.rth. Another recent study demon-
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FIG. 5. Dose response with NCA in the 
gel-based AP endonuclease assay. (A) De-
termination of NCA to inhibit Apel's 
DNA repair activity in the gel-based AP 
endonuclease assay. Pure Apel protein a t 
a concentration of 0.0875 nM '~'as incu-
bated with increasing amounts of NCA, 
appropriate buffers (5 rnM HEPES, 5 rnM 
KC!, 1 mM MgCh, 1°/o BSA, and 0.05°/o Tri-
ton X-100, pH 7.5) and a double-stranded 
oligonucleotide substrate labeled with 
hexachloro-fluoroscein phophoramidite 
label (HEX) with a tetrahydrofuran (THF) 
moiety at a concentration of 12.5 n.M. Re-
actions were incubated at 37°C for 15 min 
and '~'ere terminated by the addition of 10 
µl of formamide without dyes. Presence of 
Apel in the reactions results in the cleav-
age of the THF moiety. Resolution of the 
samples on a 20% denaturing gel with 7 M 
urea results in tv.ro bands. The slower up-
per band corresponds to the full length, la-
beled and uncleaved oligonucleotide (26 
mer), and the faster running lolver band (14 
mer) corresponds to the shorter labeled 
cleaved fragment, which is indicative of 
Apel 's cleavage activity. The gel is of a 
representative AP endonuclease assay 
with varying amounts of NCA. (B) This is 
a quantitation of the gel-based AP en-
donuclease assay results with concentra-
tion of NCA graphically represented 
against its 0/o activi ty as a histogram. Shov.rn here is the average of three experiments. The error bars represent standard er-
ror. P values '.vere calculated using Student's t test, comparing lanes with inhibitor to lane with no inhibitor. The values 
were not found to be statistically significant. 
strated that the redox function of Apel is important in he-
matopoietic differentiation (growth) by using a specifi c in-
hibitor of Apel's redox activi ty, but did not cause the cells 
to undergo apoptosis (143). These observations not only sug-
gest a crucial role for both of Ape l's functions in cellular sur-
vival and tumor promotion and progression, but also dem-
onstrate differences observed '~'hen the redox or repair 
functions are blocked. Developing specific inhibitors of the 
two functions of Apel v.rould further allow us to discern 
which of the activities of Apel are important for cancer pro-
motion and progression and normal cellular survival. Fur-
thermore, the two functions may play different roles in dif-
ferent kinds of cancer, allowing us to better understand 
tumor progression. Thus, the consequences of inhibiting of 
Apel in cancer cells point to it being a logi.ca l target in can-
cer therapeutics. Identification of molecules that specifically 
inhibit Ape l's repair or redox activity should be an effective 
means to sensitize cancer cells to chemotherapeutic agents 
and thus impact the development of new and targeted can-
cer therapies. This reviev.r will focus on repair inhibition (see 
review for information on redox inhibitors) (42). 
Existing Ape1 DNA Repair Inhibitors 
As discussed above, Apel's importance in the BER path-
way and unique role supports the hypothesis that it is a 
strong target for cancer therapy; elevated levels in cancer 
cells and knocking down Apel using siRNA leads to in-
creased ability of cancer cells to undergo apoptosis and sen-
sitization to chemotherapeutic agents (14, 37, 75, 77, 109, 114, 
121, 130). Thus, combining standard chemotherapeutic 
strategies with targeted inhibitors of Apel's DNA repair 
function ,~rould increase the effectiveness of existing 
chemotherapeutic regimens. Currently three compounds are 
kno'~'n to inhibit Apel's DNA repair activity, methoxyamine 
(MX) and two compounds, CRT0044876 or 7-nitroindole-2-
carboxylic acid (NCA) (91), and an arylstibonic acid com-
pound (118), both identified in high throughput screening 
(HTS) assays. 
Methoxyamine (MX), an indirect inhibitor of Ape1's 
repair activity 
Methoxyamine (MX) is an inhibitor of Apel vvhich inter-
acts with the aldehydic Cl atom left at the DNA abasic site 
after removal of the damaged base by a DNA glycosylase 
(86). tvfX is considered to be an indirect inhibitor of Apel in 
that it does not directly bind to Apel and inhibit its activity. 
Ra ther, MX binds to AP sites and prevents Apel and Pol f3 
from processing them further and completing repair. As a 
single agent, MX is not significantly cytotoxic, however MX 
can potentiate the cytotoxicity of alkylating agents such as 
TMZ and l,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (41, 
84, 123). TMZ predominantly alkylates guanine at the N7 
and 06 positions and adenine at the N3 position. The BER 
pathway repairs N7 and N3 alkylation damage and the ac-
APE REPAIR AND CANCER THERAPEUTICS 
37°C; 15 cycles/minute 
10000 
8000 
g 
c 6000 
D 
r 
& 
D 
• 0 
• 
a 
a 
-
• 
D 
a 
II 
• 
D 
D 
!l 
• 
• 
• 
D 
0 
• 
• 
• 
• 
a 
0 
0 • 
• 
• 
• 
• 
• 
• 
lt-
a 
• 
... 
D 
• 
- '' II D 
a 
• 
II 
D a 
• 
II 
• ~ 
a 
• 
0 
• 
• 
• 
• 
x 
-II 
l .4nM 
[ l.OnM ] 
0.7nM 
0.SnM 
[I3snM"J 
[ 0.3nM j 
0.25nM 
0.2nM 
659 
• • e I • • • • • • • 
• • • • O. I 75nM 2000 
0.075nM 
[ OnMJ 
0 2 4 6 8 10 12 14 16 
Time (minutes) 
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tion of the DNA glycosylases generate AP sites. MX binds 
to these AP sites, thus preventing Apel from completing the 
repair and stabilizing the AP site intermediate (41, 84, 123). 
Clinical trials with MX in combination w.ith TMZ are cur-
rently being pursued. A direct repair inhibitor with the abil-
ity to directly block Apel's repair activity should prove to 
be more potent in sensitizing cells to chemotherapeutic alky-
lating agents while reducing nonspecific effects. As dis-
cussed previously, MX is currently in use to block Apel's 
ability to repair AP sites. Ho"\>vever, this reagent targets the 
DNA (AP sites) and not Apel directly (86, 115). tvlX stably 
interacts vvith the Cl' aldehyde atom resulting from the re-
moval of the damaged base, producing a stable covalent 
adduct (86); Apel is unable to readily <leave the resulting 
MX- AP site (46). MX is a simple compound, H3CONH2, with 
no obvious potential for improvement in efficacy through 
derivatization and high concentrations of MX are required 
in cell-based assays (20-50 mM) in order to potentiate cell 
killing in combination \.Vith other agents (85, 94, 123, 139). In 
addition, since MX binds AP sites and not Apel directly, it 
will also affect the ability of other mammalian enzymes to 
bind DNA substrates including DNA Pol /3 (61). 
Lucanthone, a direct inhibitor of Ape 1 's repair activity 
Lucanthone, originally identified as a topoisomerase II 
poison (10), is considered to be a direct inhibitor of Apel's 
DNA repair activity. Its extensive use to treat schistosomia-
sis has shown it to be safe and nearly nontoxic from a clin-
ical standpoint (28). Cancer cells treated with lucanthone ex-
hibited a dose-dependent increase in AP sites, seemingly due 
to inhibition of Apel's repair activity and blocking an early 
step in the BER pathway (95). Pa tients \.vi th brain metastasis 
treated in combination with radiation and lucanthone 
showed increased regression of the tumors with the combi-
nation, as compared to radiation alone (28). Additionally, lu-
canthone enhances the cell killing effect of MMS and TMZ 
in breast cancer cells by the inlubition of Ape l's DNA repair 
activity (89). However, the evidence of lucanthone, also be-
ing a topoisomerase 11 inhibitor, raises the concern that the 
tumor cell killing observed could be partially attributed to 
the off-target effects of lucanthone, vvhich again points to the 
need of a robust direct inhibitor of Apel's repair function. 
7-Nitroindole-2-carboxylic acid (NGA), a direct inhibitor of 
Ape 1 's repair activity 
Madhusudhan et al. (91) identified CRT0044876 or 7-ni-
troindole-2-carboxylic acid (NCA) in a high-throughput 
screen (HTS) of a library of 5,000 drug-like compounds to be 
a direct inhibitor of Apel's repair activity with an IC5o value 
of - 3 µM. NCA is negatively charged and is reported to in-
hibit all the DNA repair activities of Apel such as the AP 
endonuclease (repair activity), 3' -phosphodiesterase, 3'-5' 
exonuclease, and 3' -phosphatase activities of Apel. Survival 
analyses in HT1080 human fibrosarcoma cells showed that 
NCA potentiates the cytotoxicity of MMS, TMZ, H20 2, and 
zeocin (91). rlowever, efforts to reproduce this repair inhi-
bition have not been realized by our laboratory and by oth-
ers (51) (Fig. SA and B). 
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FIG. 7. Scatter plot for the Z' factor 1neasure1nent. This is a sca tter plot of the positive and negative con trol data for Apel 
HTS assay. The Z' factor for the assay was calculated from the formula described by Zhang et al. (141). The Z' factor cal-
culated for this assay is 0.78. 
Arylstibonic acid compounds as inhibitors of Ape 1 's 
repair activity 
Recently, Seiple et al. (118) screened an NCI Diversity Set 
library of 2,000 compounds to identify specific inhibitors of 
Apel. The authors identified an arylstibonic acid co1npound 
13755 which has a negative cl:iarge, as an inhibitor of Apel's 
DNA repair activity. This compound shows partial mixed 
type inhibition in that it binds both to the enzyme and the en-
zyme substrate complex. Even though these compounds have 
been reported to inhibit Apel's DNA repair activity in vitro, 
they have virtually no cellular uptake and are less attractive 
as translational agents. Treatment of 1-IOS osteosarcoma cells 
with 5 µM of the compound in the presence of MMS did not 
shov.r decreased survival in cytotoxicity assays (118). 
Need for Specific Inhibitors of Ape1 's DNA 
Repair Activity 
There is a clear need for a specific repair inhibitor of Apel 
in order to effectively determine the role of Apel 's repair ac-
tivity in potentiating the effects of alkylating cl1emothera· 
peutic agents. This is required given the importance of in· 
hibiting Apel using siRNA leading to sensitization of cancer 
cells to chemotherapeutic agents (14, 15, 75, 81, 87, 114, 121, 
129, 130). However, these studies remove all of Ape l's func-
tions (repair and redox) as well as Apel's protein- protein 
interactions (38), making the data difficult to interpret. Thus, 
identifying specific and potent Apel repair inhibitors would 
facilitate the understanding of Apel not only in cancer, but 
also in dividing normal cells (bone marrov.r, gut, etc), non-
dividing normal cells (neurons), and other diseases where 
Apel has been implicated {17, 47, 60, 67, 106, 124). In addi-
tion, these small molecule inhibitors will allow the specific 
inhibition of Apel's repair function v.rhile keeping its post· 
translational modifications (18, 68, 70, 97) and subcellular lo-
cation of Apel intact and in determining the effect of block-
ing Apel's function on these subcellular events (30, 107, 124). 
In summary, identification of specific inhibitors of Apel's 
repair activity \-vill further our ability to determine the role 
it plays in cancer promotion and progression, thus making 
a productive target of chemoprevention. 
High Throughput Screening (HTS) Methodology to 
Identify Specific Inhibitors of Ape1 's DNA 
Repair Activity 
High throughput screening (HTS) is an efficient scientific 
method that allows the assay o f large numbers of varied 
chemical compounds against biological targets in a rela tively 
short period of time. HTS assays are either entirely or par-
tially automated and can be carried out in the 96-well or 384-
well forma t. Robotic automation in HTS helps speed up the 
process of drug discovery and facilitates the generation of a 
large amount of scientific data in a short time-frame. Several 
different libraries of synthetic and drug-like compounds are 
available for HTS. Typically, the first round of HTS is car· 
ried out ,~rith a fixed concentration (1-10 µM) of the cherni· 
cal compound. The positive 'luts' identified in the pri1nary 
assay can be re-screened in the same assay and these hits are 
then followed up in secondary assays to validate them, de-
termine an TC50 concentration, and perform functional cel-
lular assays. Thus, HTS is a promising and rapid methodol-
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FIG. 8. Dose response w ith HTS compound AB-01 in the gel-based AP endonuclease assay. {A) The ability of the HTS 
compound AB-01 to inhibit Apel's DNA repair activity in the gel-based AP endonuclease assay was determined. 0.0875 
nM concentration of pure Apel protein was incubated with increasing amounts of AB-01, appropriate buffers (5 mM HEPES, 
5 mM KCl, 1 mM MgCl2, 1 o/o BSA, and 0.05°/o Triton X-100, pH 7.5) and a double-stranded hexachloro-fluoroscein 
phophoramidite labeled (HEX) oligonucleotide substrate with a tetrahydrofuran (THF) moiety at a concentration of 12.5 
nM. Reactions were incubated at 37°C for 15 min and were terminated by the addition of 10 µ, l formamide without dyes. 
Apel in the reaction cleaves the THF moiety and resolution of the samples on a 20°/o denaturing gel with 7 M Urea results 
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ues were calculated using Student's t-test, comparing lanes with inhibitor to lane with no inhibitor (*p < 0.05 and **p < 
0.01). 
ogy to identify potential modulators of the biological activ-
ity of the target from a large number of compounds. 
Efforts are under way in our laboratory to identify and de-
velop a novel inhibitor of Apel's DNA repair activity using 
the HTS methodology. We have modified the fluorescence-
based high throughput screening assay described by Mad-
husudhan et al. (91) to screen a library of 60,000 synthetic 
drug-like compounds \.Yhich follow Lipinsky's rule of five 
(83) from Chemical Diversity Ltd Inc. (San Diego, CA). We 
used purified Apel protein at a concentration that showed 
a linear range for the assay over a period of time (Fig. 6). 1n 
order to determine the reliability of the assay, we performed 
control experiments and calculated the Z'-factor score of0.78 
(Fig. 7). The Z' -factor reflects the dynamic range between the 
positive and negative controls and is also a reflection of the 
reproducibility of the data and reliability of the assay. The 
Z'-factor values range from 0.5 to 1.0, and a score above 0.5 
is an indication of a good assay, \.Yith 1 being a perfect as-
say (142). After an initial screen of the 60,000 compound li-
brary, we identified 190 compounds showing > 50°/o inhibi-
tion of Apel's DNA repair activity. Of the 190 con1pounds, 
174 \.Vere available and re-screened in the same HTS assay. 
Forty-five compounds showing 2::40°/o inhibition of Apel's 
repair activity were identified after two rounds of HTS 
screening. These 45 compounds are now being further vali-
dated in a secondary gel-based AP endonuclease assay to 
662 
further assess inhibition of the compounds. On completion 
of the validation of the 45 compounds in the secondary as-
says, promising compounds will then be tested for their abil-
ity to specifically inhibit Apel's DNA repair ability in in vitro 
cellular assays, including cell growth, cytotoxicity, and apop-
tosis assays. 
Jn the secondary gel-based AP endonuclease assay, a con-
centration of Apel protein in the linear range was titrated 
against a range of concentrations of the compounds. As a 
control, all the compounds tested in the gel-based AP en-
donuclease assay are compared to NCA, a known inhibitor 
of Apel's DNA repair activity, at a concentration of 10 µM 
(91). One of the compounds identified in the HTS screen, AB-
01, demonstrated consistent inhibition of Apel's DNA repair 
activity both in the HTS and the secondary gel-based AP en-
donuclease assay. As seen in Fig. 8A and B, compound AB-
01 is able to inhibit Apel's DNA repair activity. At a con-
centra tion of 10 µM, inhibition o f Apel's DNA repair activity 
by AB-01 is better than that den1onstrated by NCA at the 
same concentration. 
Conclusions 
Ability of cancer cells to recognize and repair chemother-
apy-induced damage is an important factor in resistance to 
chemotherapy (90). Therefore, inhibiting DNA damage re-
pair pathways and using inhibitors against specific proteins 
of these pathways is an excellent strategy to develop targeted 
therapies for cancer treatment. (12, 31, 59, 90, 92). Apel is a 
an essential protein functioning in the BER pathway which 
repairs damage caused by endogenous as well as exogenous 
DNA base damage including chemotherapy-induced DNA 
damage (24, 37, 44). Apel is unique such that it is the only 
cellular protein that can process the AP sites generated as a 
result of the action of the DNA glycosylases. It is also the 
only DNA repair and redox protein in the cells and there is 
no backup for the critically important repair function of Apel 
in cancer cells. This makes it a unique target, particularly 
since it has tvvo important functions that work independently 
of one another. In addition to its important role in normal 
cellular functioning, altered or elevated levels of Apel have 
been observed in a variety of cancers, including breast can-
cer, gliomas, sarcomas (osteosarcomas, rhabdomyosarco-
mas), ovarian and multiple myeloma, among others (37, 75, 
77, 109, 114, 121, 130) which have been speculated to be a 
cause of resistance to chemotherapy. In addition, these 
heightened levels of Apel have been linked to tumor pro-
motion, progression, and poor prognosis associated with 
shorter relapse-free survival and poor outcome from che-
motherapy (77). There is a vast amount of data shov.ring that 
downregulating or inhibiting Apel in cancer cells using RNA 
interference and DNA antisense oligonucleotide techniques 
can sensitize them to laboratory and clinical chemothera-
peutic agents (14, 15, 75, 81, 114, 121, 129, 131). Since Apel 
is involved in the repair of DNA damaged by chemothera-
peutic agents, identifying selective inhibitors of the DNA re-
pair or redox activities of Apel would make it an excellent 
target, both from a single agent approach and in combina-
tion with chemotherapy and IR. Additionally, it may be cou-
pled v.rith other specific molecular targets in cell cycle or 
other pathways to thwart the cancer cell from skirting cell 
death and prevent drug resistance from occurring. 
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